The latest from CDMOs, CMOs, and suppliers featuring WuXi Biologics, Thermo Fisher Scientific, and PCI Pharma Services, Mikart and Benuvia.

Biologics Manufacturing 
* WuXi Biologics Announces Structural Completion of Microbial Mfg Facility  
* Thermo Fisher Opens New Bioprocess Design Center
Formulation Development/Drug Product Manufacturing 
* PCI Pharma Services Expanding Sterile Fill-Finish and Drug-Device Mfg 
* Mikart, Benuvia Form Strategic Partnership

---

Biologics Manufacturing 

WuXi Biologics Announces Structural Completion of Microbial Mfg Facility 
WuXi Biologics, a Wuxi, China-based CDMO of biologics, has announced the structural completion and key equipment arrival for its microbial commercial manufacturing site in Chengdu, China.  

The company broke ground in June 2025 on the 95,000-square-meter microbial manufacturing site, which is designed for commercial drug-substance (DS) and drug-product (DP) manufacturing of microbial-derived biologics. Upon completion, the manufacturing site will be equipped with a 15,000-L fermenter to enable up to 110 DS batches annually, with long-term expansion potential up to 60,000 L. The site will also feature a dual-chamber lyophilization production line, jointly established with Visen Pharmaceuticals, a Shanghai-based bio/pharmaceutical company, along with a vial-filling line for commercial DP manufacturing capacity of more than 10 million vials per year. The company is targeting GMP release for production by the end of 2026. 

Source: WuXi Biologics 

---

Thermo Fisher Opens New Bioprocess Design Center 
Thermo Fisher Scientific has opened a new US bioprocess design center (BDC) at the company’s site in Plainville, Massachusetts. It features 4,000 square feet of laboratory and training space for developing biologics, including vaccines and cell and gene therapies.  

Source: Thermo Fisher Scientific 

---

Formulation Development/Drug Product Manufacturing 

PCI Pharma Services Expanding Sterile Fill-Finish and Drug-Device Mfg 
PCI Pharma Services, a Philadelphia, Pennsylvania-based CDMO, has announced a series of investments to expand its sterile fill–finish and advanced drug-delivery capabilities. It is part of a broader $1-billion expansion plan across the company’s US and European operations. 

A key project is a $100-million expansion at its site in San Diego, California, for a high-speed isolator filling line for ready-to-use prefilled syringes and cartridges. Scheduled to be operational in the first half of 2028, the line will more than double the site’s existing syringe- and cartridge-filling capacity. It will be PCI’s second isolator fill–finish line in San Diego. The site also provides large-scale aseptic filling for prefilled syringes and cartridges, alongside specialized capabilities in oligonucleotides, peptides, complex formulations and lyophilization for injectables such as nanoparticles, mRNA, monoclonal antibodies, proteins, and highly potent products. 

In addition, the company is commissioning a GMP isolator vial and lyophilization line at its site in Bedford, New Hampshire. Upon commencing full-scale production, which was scheduled for late April (April 2026), the site will be capable of producing batch sizes of up to 300,000 vials at 400 units per minute, for an annual total of 33 million. The company has also invested in automated visual inspection (AVI) systems for sterile fill–finish applications at its sites in San Diego and Bedford, New Hampshire. In total, PCI’s US-based AVI infrastructure supports more than 70 million prefilled syringes and cartridges and 40 million vials per year. 

In addition, in 2027, PCI will add a third autoinjector line to bring its US autoinjector and device assembly capacity to more than 250 million units per year. 

In conjunction with expanding its manufacturing platform, PCI is investing in dedicated Development Centers of Excellence (CoE) in Bedford, New Hampshire, and León, Spain. The CoEs will feature development capabilities in lyophilization, formulation, analytical support, drug-device combination assets, long-acting injectables and ophthalmic products. They will handle both highly potent and non-potent small molecule and biologic modalities in vial, prefilled syringe and cartridge presentations. The Bedford Development CoE is expected to be operational this month (May 2026) with León following in June (June 2026). 

Source: PCI Pharma Services 

Mikart, Benuvia Form Strategic Partnership
Mikart, a contract provider of formulation development, analytical testing, and finished dose manufacturing, and Benuvia Operations, a CDMO with specialized development and manufacturing capabilities in controlled substance and complex active pharmaceutical ingredients, have formed a strategic co-marketing partnership to combine their complementary capabilities to provide end-to-end capabilities spanning drug-substance development through finished drug product manufacturing.

Under the agreement, both organizations will jointly promote their services on a global scale and collaborate on business development initiatives. These efforts will include shared customer engagements, coordinated presentations, participation in major industry events, and targeted outreach to prospective clients.

Source: Mikart